Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization.

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Hedge fund Starboard in Q2 took a new position in TripAdvisor (NASDAQ:TRIP) and iShares Russell 2000 ETF (IWM), boosted its positions in Salesforce (NYSE:CRM) and Pfizer (NYSE:PFE) and trimmed its ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...